nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00153	0.00234	CcSEcCtD
Cevimeline—Arthritis—Capecitabine—esophageal cancer	0.00152	0.00234	CcSEcCtD
Cevimeline—Vaginal inflammation—Methotrexate—esophageal cancer	0.00152	0.00233	CcSEcCtD
Cevimeline—Pulmonary embolism—Methotrexate—esophageal cancer	0.00152	0.00233	CcSEcCtD
Cevimeline—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00152	0.00233	CcSEcCtD
Cevimeline—Myocardial infarction—Cisplatin—esophageal cancer	0.00152	0.00233	CcSEcCtD
Cevimeline—Stomatitis—Cisplatin—esophageal cancer	0.00151	0.00231	CcSEcCtD
Cevimeline—Conjunctivitis—Cisplatin—esophageal cancer	0.0015	0.00231	CcSEcCtD
Cevimeline—Hyponatraemia—Capecitabine—esophageal cancer	0.00149	0.00228	CcSEcCtD
Cevimeline—Cystitis noninfective—Methotrexate—esophageal cancer	0.00148	0.00227	CcSEcCtD
Cevimeline—Melaena—Methotrexate—esophageal cancer	0.00148	0.00227	CcSEcCtD
Cevimeline—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00148	0.00227	CcSEcCtD
Cevimeline—Diplopia—Capecitabine—esophageal cancer	0.00148	0.00227	CcSEcCtD
Cevimeline—Pain in extremity—Capecitabine—esophageal cancer	0.00148	0.00227	CcSEcCtD
Cevimeline—Osteoarthritis—Capecitabine—esophageal cancer	0.00148	0.00227	CcSEcCtD
Cevimeline—Cystitis—Methotrexate—esophageal cancer	0.00147	0.00225	CcSEcCtD
Cevimeline—Migraine—Capecitabine—esophageal cancer	0.00146	0.00223	CcSEcCtD
Cevimeline—Skin exfoliation—Methotrexate—esophageal cancer	0.00145	0.00222	CcSEcCtD
Cevimeline—Vaginal infection—Methotrexate—esophageal cancer	0.00143	0.0022	CcSEcCtD
Cevimeline—Face oedema—Capecitabine—esophageal cancer	0.00143	0.00219	CcSEcCtD
Cevimeline—Urinary retention—Capecitabine—esophageal cancer	0.00141	0.00216	CcSEcCtD
Cevimeline—Mood swings—Capecitabine—esophageal cancer	0.0014	0.00215	CcSEcCtD
Cevimeline—Coma—Methotrexate—esophageal cancer	0.00139	0.00213	CcSEcCtD
Cevimeline—Dehydration—Capecitabine—esophageal cancer	0.00138	0.00211	CcSEcCtD
Cevimeline—Mouth ulceration—Methotrexate—esophageal cancer	0.00137	0.0021	CcSEcCtD
Cevimeline—Neoplasm—Methotrexate—esophageal cancer	0.00137	0.0021	CcSEcCtD
Cevimeline—Bladder pain—Methotrexate—esophageal cancer	0.00137	0.0021	CcSEcCtD
Cevimeline—Urine output increased—Methotrexate—esophageal cancer	0.00137	0.0021	CcSEcCtD
Cevimeline—Urethral disorder—Cisplatin—esophageal cancer	0.00136	0.00209	CcSEcCtD
Cevimeline—Dry skin—Capecitabine—esophageal cancer	0.00136	0.00208	CcSEcCtD
Cevimeline—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00135	0.00207	CcSEcCtD
Cevimeline—Hypokalaemia—Capecitabine—esophageal cancer	0.00135	0.00207	CcSEcCtD
Cevimeline—Visual impairment—Cisplatin—esophageal cancer	0.00134	0.00205	CcSEcCtD
Cevimeline—Sepsis—Methotrexate—esophageal cancer	0.00132	0.00202	CcSEcCtD
Cevimeline—Gastritis—Capecitabine—esophageal cancer	0.00131	0.00201	CcSEcCtD
Cevimeline—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00131	0.002	CcSEcCtD
Cevimeline—Muscular weakness—Capecitabine—esophageal cancer	0.00131	0.002	CcSEcCtD
Cevimeline—Eye disorder—Cisplatin—esophageal cancer	0.0013	0.00199	CcSEcCtD
Cevimeline—Tinnitus—Cisplatin—esophageal cancer	0.0013	0.00199	CcSEcCtD
Cevimeline—Lymphadenopathy—Methotrexate—esophageal cancer	0.00129	0.00198	CcSEcCtD
Cevimeline—Flushing—Cisplatin—esophageal cancer	0.00129	0.00198	CcSEcCtD
Cevimeline—Cardiac disorder—Cisplatin—esophageal cancer	0.00129	0.00198	CcSEcCtD
Cevimeline—Abdominal distension—Capecitabine—esophageal cancer	0.00129	0.00197	CcSEcCtD
Cevimeline—Asthma—Capecitabine—esophageal cancer	0.00128	0.00196	CcSEcCtD
Cevimeline—Dysphagia—Capecitabine—esophageal cancer	0.00128	0.00196	CcSEcCtD
Cevimeline—Thrombophlebitis—Methotrexate—esophageal cancer	0.00127	0.00195	CcSEcCtD
Cevimeline—Diabetes mellitus—Methotrexate—esophageal cancer	0.00127	0.00194	CcSEcCtD
Cevimeline—Bronchospasm—Capecitabine—esophageal cancer	0.00126	0.00193	CcSEcCtD
Cevimeline—Polyuria—Methotrexate—esophageal cancer	0.00125	0.00192	CcSEcCtD
Cevimeline—Sweating increased—Capecitabine—esophageal cancer	0.00125	0.00191	CcSEcCtD
Cevimeline—Angina pectoris—Capecitabine—esophageal cancer	0.00125	0.00191	CcSEcCtD
Cevimeline—Arrhythmia—Cisplatin—esophageal cancer	0.00124	0.0019	CcSEcCtD
Cevimeline—Bronchitis—Capecitabine—esophageal cancer	0.00123	0.00189	CcSEcCtD
Cevimeline—Alopecia—Cisplatin—esophageal cancer	0.00123	0.00188	CcSEcCtD
Cevimeline—Malnutrition—Cisplatin—esophageal cancer	0.00121	0.00185	CcSEcCtD
Cevimeline—Dysuria—Capecitabine—esophageal cancer	0.0012	0.00183	CcSEcCtD
Cevimeline—Flatulence—Cisplatin—esophageal cancer	0.00119	0.00183	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00119	0.00182	CcSEcCtD
Cevimeline—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00117	0.00179	CcSEcCtD
Cevimeline—Weight increased—Capecitabine—esophageal cancer	0.00116	0.00179	CcSEcCtD
Cevimeline—Muscle spasms—Cisplatin—esophageal cancer	0.00116	0.00178	CcSEcCtD
Cevimeline—Weight decreased—Capecitabine—esophageal cancer	0.00116	0.00177	CcSEcCtD
Cevimeline—Hyperglycaemia—Capecitabine—esophageal cancer	0.00115	0.00177	CcSEcCtD
Cevimeline—Pneumonia—Capecitabine—esophageal cancer	0.00115	0.00176	CcSEcCtD
Cevimeline—Depression—Capecitabine—esophageal cancer	0.00114	0.00174	CcSEcCtD
Cevimeline—Tremor—Cisplatin—esophageal cancer	0.00113	0.00174	CcSEcCtD
Cevimeline—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00112	0.00172	CcSEcCtD
Cevimeline—Ill-defined disorder—Cisplatin—esophageal cancer	0.00112	0.00172	CcSEcCtD
Cevimeline—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00112	0.00171	CcSEcCtD
Cevimeline—Myocardial infarction—Capecitabine—esophageal cancer	0.00112	0.00171	CcSEcCtD
Cevimeline—Anaemia—Cisplatin—esophageal cancer	0.00112	0.00171	CcSEcCtD
Cevimeline—Stomatitis—Capecitabine—esophageal cancer	0.00111	0.0017	CcSEcCtD
Cevimeline—Conjunctivitis—Capecitabine—esophageal cancer	0.00111	0.0017	CcSEcCtD
Cevimeline—Urinary tract infection—Capecitabine—esophageal cancer	0.00111	0.0017	CcSEcCtD
Cevimeline—Osteoarthritis—Methotrexate—esophageal cancer	0.0011	0.00169	CcSEcCtD
Cevimeline—Malaise—Cisplatin—esophageal cancer	0.00109	0.00167	CcSEcCtD
Cevimeline—Haematuria—Capecitabine—esophageal cancer	0.00109	0.00167	CcSEcCtD
Cevimeline—Leukopenia—Cisplatin—esophageal cancer	0.00108	0.00166	CcSEcCtD
Cevimeline—Epistaxis—Capecitabine—esophageal cancer	0.00108	0.00165	CcSEcCtD
Cevimeline—Agranulocytosis—Capecitabine—esophageal cancer	0.00106	0.00163	CcSEcCtD
Cevimeline—Convulsion—Cisplatin—esophageal cancer	0.00105	0.00161	CcSEcCtD
Cevimeline—Mood swings—Methotrexate—esophageal cancer	0.00104	0.0016	CcSEcCtD
Cevimeline—Myalgia—Cisplatin—esophageal cancer	0.00103	0.00158	CcSEcCtD
Cevimeline—Haemoglobin—Capecitabine—esophageal cancer	0.00103	0.00158	CcSEcCtD
Cevimeline—Rhinitis—Capecitabine—esophageal cancer	0.00103	0.00157	CcSEcCtD
Cevimeline—Anxiety—Cisplatin—esophageal cancer	0.00103	0.00157	CcSEcCtD
Cevimeline—Haemorrhage—Capecitabine—esophageal cancer	0.00102	0.00157	CcSEcCtD
Cevimeline—Hypoaesthesia—Capecitabine—esophageal cancer	0.00102	0.00156	CcSEcCtD
Cevimeline—Discomfort—Cisplatin—esophageal cancer	0.00102	0.00156	CcSEcCtD
Cevimeline—Pharyngitis—Capecitabine—esophageal cancer	0.00102	0.00156	CcSEcCtD
Cevimeline—Oedema peripheral—Capecitabine—esophageal cancer	0.00101	0.00155	CcSEcCtD
Cevimeline—Urethral disorder—Capecitabine—esophageal cancer	0.001	0.00154	CcSEcCtD
Cevimeline—Oedema—Cisplatin—esophageal cancer	0.000987	0.00151	CcSEcCtD
Cevimeline—Visual impairment—Capecitabine—esophageal cancer	0.000987	0.00151	CcSEcCtD
Cevimeline—Infection—Cisplatin—esophageal cancer	0.00098	0.0015	CcSEcCtD
Cevimeline—Nervous system disorder—Cisplatin—esophageal cancer	0.000968	0.00148	CcSEcCtD
Cevimeline—Thrombocytopenia—Cisplatin—esophageal cancer	0.000966	0.00148	CcSEcCtD
Cevimeline—Tachycardia—Cisplatin—esophageal cancer	0.000963	0.00148	CcSEcCtD
Cevimeline—Skin disorder—Cisplatin—esophageal cancer	0.000958	0.00147	CcSEcCtD
Cevimeline—Eye disorder—Capecitabine—esophageal cancer	0.000957	0.00147	CcSEcCtD
Cevimeline—Tinnitus—Capecitabine—esophageal cancer	0.000955	0.00146	CcSEcCtD
Cevimeline—Hyperhidrosis—Cisplatin—esophageal cancer	0.000954	0.00146	CcSEcCtD
Cevimeline—Asthma—Methotrexate—esophageal cancer	0.000952	0.00146	CcSEcCtD
Cevimeline—Cardiac disorder—Capecitabine—esophageal cancer	0.00095	0.00146	CcSEcCtD
Cevimeline—Flushing—Capecitabine—esophageal cancer	0.00095	0.00146	CcSEcCtD
Cevimeline—Eosinophilia—Methotrexate—esophageal cancer	0.000943	0.00145	CcSEcCtD
Cevimeline—Anorexia—Cisplatin—esophageal cancer	0.000941	0.00144	CcSEcCtD
Cevimeline—Angiopathy—Capecitabine—esophageal cancer	0.000929	0.00142	CcSEcCtD
Cevimeline—Hypotension—Cisplatin—esophageal cancer	0.000922	0.00141	CcSEcCtD
Cevimeline—Chills—Capecitabine—esophageal cancer	0.000919	0.00141	CcSEcCtD
Cevimeline—Arrhythmia—Capecitabine—esophageal cancer	0.000915	0.0014	CcSEcCtD
Cevimeline—Alopecia—Capecitabine—esophageal cancer	0.000905	0.00139	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000899	0.00138	CcSEcCtD
Cevimeline—Malnutrition—Capecitabine—esophageal cancer	0.000891	0.00137	CcSEcCtD
Cevimeline—Dysuria—Methotrexate—esophageal cancer	0.00089	0.00137	CcSEcCtD
Cevimeline—Paraesthesia—Cisplatin—esophageal cancer	0.000886	0.00136	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000885	0.00136	CcSEcCtD
Cevimeline—Dyspnoea—Cisplatin—esophageal cancer	0.00088	0.00135	CcSEcCtD
Cevimeline—Flatulence—Capecitabine—esophageal cancer	0.000878	0.00135	CcSEcCtD
Cevimeline—Erectile dysfunction—Methotrexate—esophageal cancer	0.000877	0.00134	CcSEcCtD
Cevimeline—Dysgeusia—Capecitabine—esophageal cancer	0.000873	0.00134	CcSEcCtD
Cevimeline—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000869	0.00133	CcSEcCtD
Cevimeline—Back pain—Capecitabine—esophageal cancer	0.000862	0.00132	CcSEcCtD
Cevimeline—Decreased appetite—Cisplatin—esophageal cancer	0.000858	0.00132	CcSEcCtD
Cevimeline—Muscle spasms—Capecitabine—esophageal cancer	0.000857	0.00131	CcSEcCtD
Cevimeline—Pneumonia—Methotrexate—esophageal cancer	0.000854	0.00131	CcSEcCtD
Cevimeline—Depression—Methotrexate—esophageal cancer	0.000847	0.0013	CcSEcCtD
Cevimeline—Pain—Cisplatin—esophageal cancer	0.000844	0.00129	CcSEcCtD
Cevimeline—Tremor—Capecitabine—esophageal cancer	0.000835	0.00128	CcSEcCtD
Cevimeline—Stomatitis—Methotrexate—esophageal cancer	0.000828	0.00127	CcSEcCtD
Cevimeline—Ill-defined disorder—Capecitabine—esophageal cancer	0.000827	0.00127	CcSEcCtD
Cevimeline—Conjunctivitis—Methotrexate—esophageal cancer	0.000825	0.00127	CcSEcCtD
Cevimeline—Anaemia—Capecitabine—esophageal cancer	0.000824	0.00126	CcSEcCtD
Cevimeline—Feeling abnormal—Cisplatin—esophageal cancer	0.000813	0.00125	CcSEcCtD
Cevimeline—Haematuria—Methotrexate—esophageal cancer	0.00081	0.00124	CcSEcCtD
Cevimeline—Malaise—Capecitabine—esophageal cancer	0.000804	0.00123	CcSEcCtD
Cevimeline—Epistaxis—Methotrexate—esophageal cancer	0.000801	0.00123	CcSEcCtD
Cevimeline—Vertigo—Capecitabine—esophageal cancer	0.000801	0.00123	CcSEcCtD
Cevimeline—Syncope—Capecitabine—esophageal cancer	0.000799	0.00123	CcSEcCtD
Cevimeline—Leukopenia—Capecitabine—esophageal cancer	0.000798	0.00122	CcSEcCtD
Cevimeline—Agranulocytosis—Methotrexate—esophageal cancer	0.000792	0.00122	CcSEcCtD
Cevimeline—Palpitations—Capecitabine—esophageal cancer	0.000788	0.00121	CcSEcCtD
Cevimeline—Loss of consciousness—Capecitabine—esophageal cancer	0.000783	0.0012	CcSEcCtD
Cevimeline—Body temperature increased—Cisplatin—esophageal cancer	0.00078	0.0012	CcSEcCtD
Cevimeline—Cough—Capecitabine—esophageal cancer	0.000778	0.00119	CcSEcCtD
Cevimeline—Hypertension—Capecitabine—esophageal cancer	0.000769	0.00118	CcSEcCtD
Cevimeline—Haemoglobin—Methotrexate—esophageal cancer	0.000766	0.00117	CcSEcCtD
Cevimeline—Haemorrhage—Methotrexate—esophageal cancer	0.000762	0.00117	CcSEcCtD
Cevimeline—Myalgia—Capecitabine—esophageal cancer	0.000759	0.00116	CcSEcCtD
Cevimeline—Chest pain—Capecitabine—esophageal cancer	0.000759	0.00116	CcSEcCtD
Cevimeline—Arthralgia—Capecitabine—esophageal cancer	0.000759	0.00116	CcSEcCtD
Cevimeline—Pharyngitis—Methotrexate—esophageal cancer	0.000756	0.00116	CcSEcCtD
Cevimeline—Anxiety—Capecitabine—esophageal cancer	0.000756	0.00116	CcSEcCtD
Cevimeline—Discomfort—Capecitabine—esophageal cancer	0.00075	0.00115	CcSEcCtD
Cevimeline—Urethral disorder—Methotrexate—esophageal cancer	0.000747	0.00115	CcSEcCtD
Cevimeline—Visual impairment—Methotrexate—esophageal cancer	0.000735	0.00113	CcSEcCtD
Cevimeline—Confusional state—Capecitabine—esophageal cancer	0.000733	0.00112	CcSEcCtD
Cevimeline—Oedema—Capecitabine—esophageal cancer	0.000727	0.00112	CcSEcCtD
Cevimeline—Hypersensitivity—Cisplatin—esophageal cancer	0.000727	0.00111	CcSEcCtD
Cevimeline—Infection—Capecitabine—esophageal cancer	0.000723	0.00111	CcSEcCtD
Cevimeline—Shock—Capecitabine—esophageal cancer	0.000716	0.0011	CcSEcCtD
Cevimeline—Nervous system disorder—Capecitabine—esophageal cancer	0.000713	0.00109	CcSEcCtD
Cevimeline—Eye disorder—Methotrexate—esophageal cancer	0.000712	0.00109	CcSEcCtD
Cevimeline—Thrombocytopenia—Capecitabine—esophageal cancer	0.000712	0.00109	CcSEcCtD
Cevimeline—Tinnitus—Methotrexate—esophageal cancer	0.000711	0.00109	CcSEcCtD
Cevimeline—Tachycardia—Capecitabine—esophageal cancer	0.00071	0.00109	CcSEcCtD
Cevimeline—Asthenia—Cisplatin—esophageal cancer	0.000708	0.00109	CcSEcCtD
Cevimeline—Cardiac disorder—Methotrexate—esophageal cancer	0.000707	0.00108	CcSEcCtD
Cevimeline—Skin disorder—Capecitabine—esophageal cancer	0.000707	0.00108	CcSEcCtD
Cevimeline—Hyperhidrosis—Capecitabine—esophageal cancer	0.000703	0.00108	CcSEcCtD
Cevimeline—Anorexia—Capecitabine—esophageal cancer	0.000693	0.00106	CcSEcCtD
Cevimeline—Angiopathy—Methotrexate—esophageal cancer	0.000692	0.00106	CcSEcCtD
Cevimeline—Chills—Methotrexate—esophageal cancer	0.000684	0.00105	CcSEcCtD
Cevimeline—Hypotension—Capecitabine—esophageal cancer	0.00068	0.00104	CcSEcCtD
Cevimeline—Diarrhoea—Cisplatin—esophageal cancer	0.000675	0.00104	CcSEcCtD
Cevimeline—Alopecia—Methotrexate—esophageal cancer	0.000674	0.00103	CcSEcCtD
Cevimeline—Malnutrition—Methotrexate—esophageal cancer	0.000663	0.00102	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000663	0.00102	CcSEcCtD
Cevimeline—Insomnia—Capecitabine—esophageal cancer	0.000658	0.00101	CcSEcCtD
Cevimeline—Paraesthesia—Capecitabine—esophageal cancer	0.000653	0.001	CcSEcCtD
Cevimeline—Dysgeusia—Methotrexate—esophageal cancer	0.00065	0.000996	CcSEcCtD
Cevimeline—Dyspnoea—Capecitabine—esophageal cancer	0.000649	0.000995	CcSEcCtD
Cevimeline—Back pain—Methotrexate—esophageal cancer	0.000642	0.000984	CcSEcCtD
Cevimeline—Dyspepsia—Capecitabine—esophageal cancer	0.00064	0.000982	CcSEcCtD
Cevimeline—Decreased appetite—Capecitabine—esophageal cancer	0.000632	0.00097	CcSEcCtD
Cevimeline—Vomiting—Cisplatin—esophageal cancer	0.000627	0.000962	CcSEcCtD
Cevimeline—Fatigue—Capecitabine—esophageal cancer	0.000627	0.000962	CcSEcCtD
Cevimeline—Rash—Cisplatin—esophageal cancer	0.000622	0.000954	CcSEcCtD
Cevimeline—Pain—Capecitabine—esophageal cancer	0.000622	0.000954	CcSEcCtD
Cevimeline—Constipation—Capecitabine—esophageal cancer	0.000622	0.000954	CcSEcCtD
Cevimeline—Dermatitis—Cisplatin—esophageal cancer	0.000622	0.000953	CcSEcCtD
Cevimeline—Ill-defined disorder—Methotrexate—esophageal cancer	0.000616	0.000944	CcSEcCtD
Cevimeline—Anaemia—Methotrexate—esophageal cancer	0.000613	0.00094	CcSEcCtD
Cevimeline—Feeling abnormal—Capecitabine—esophageal cancer	0.000599	0.000919	CcSEcCtD
Cevimeline—Malaise—Methotrexate—esophageal cancer	0.000598	0.000918	CcSEcCtD
Cevimeline—Vertigo—Methotrexate—esophageal cancer	0.000596	0.000914	CcSEcCtD
Cevimeline—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000595	0.000912	CcSEcCtD
Cevimeline—Leukopenia—Methotrexate—esophageal cancer	0.000594	0.000911	CcSEcCtD
Cevimeline—Nausea—Cisplatin—esophageal cancer	0.000586	0.000899	CcSEcCtD
Cevimeline—Cough—Methotrexate—esophageal cancer	0.000579	0.000888	CcSEcCtD
Cevimeline—Urticaria—Capecitabine—esophageal cancer	0.000578	0.000886	CcSEcCtD
Cevimeline—Body temperature increased—Capecitabine—esophageal cancer	0.000575	0.000882	CcSEcCtD
Cevimeline—Abdominal pain—Capecitabine—esophageal cancer	0.000575	0.000882	CcSEcCtD
Cevimeline—Convulsion—Methotrexate—esophageal cancer	0.000575	0.000882	CcSEcCtD
Cevimeline—Arthralgia—Methotrexate—esophageal cancer	0.000565	0.000866	CcSEcCtD
Cevimeline—Chest pain—Methotrexate—esophageal cancer	0.000565	0.000866	CcSEcCtD
Cevimeline—Myalgia—Methotrexate—esophageal cancer	0.000565	0.000866	CcSEcCtD
Cevimeline—Discomfort—Methotrexate—esophageal cancer	0.000558	0.000856	CcSEcCtD
Cevimeline—Confusional state—Methotrexate—esophageal cancer	0.000546	0.000837	CcSEcCtD
Cevimeline—Infection—Methotrexate—esophageal cancer	0.000538	0.000825	CcSEcCtD
Cevimeline—Hypersensitivity—Capecitabine—esophageal cancer	0.000536	0.000822	CcSEcCtD
Cevimeline—Nervous system disorder—Methotrexate—esophageal cancer	0.000531	0.000814	CcSEcCtD
Cevimeline—Thrombocytopenia—Methotrexate—esophageal cancer	0.00053	0.000813	CcSEcCtD
Cevimeline—Skin disorder—Methotrexate—esophageal cancer	0.000526	0.000807	CcSEcCtD
Cevimeline—Hyperhidrosis—Methotrexate—esophageal cancer	0.000523	0.000803	CcSEcCtD
Cevimeline—Asthenia—Capecitabine—esophageal cancer	0.000522	0.0008	CcSEcCtD
Cevimeline—Anorexia—Methotrexate—esophageal cancer	0.000516	0.000792	CcSEcCtD
Cevimeline—Pruritus—Capecitabine—esophageal cancer	0.000515	0.000789	CcSEcCtD
Cevimeline—Hypotension—Methotrexate—esophageal cancer	0.000506	0.000776	CcSEcCtD
Cevimeline—Diarrhoea—Capecitabine—esophageal cancer	0.000498	0.000763	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000493	0.000757	CcSEcCtD
Cevimeline—Insomnia—Methotrexate—esophageal cancer	0.00049	0.000751	CcSEcCtD
Cevimeline—Paraesthesia—Methotrexate—esophageal cancer	0.000486	0.000746	CcSEcCtD
Cevimeline—Dyspnoea—Methotrexate—esophageal cancer	0.000483	0.00074	CcSEcCtD
Cevimeline—Somnolence—Methotrexate—esophageal cancer	0.000481	0.000738	CcSEcCtD
Cevimeline—Dizziness—Capecitabine—esophageal cancer	0.000481	0.000738	CcSEcCtD
Cevimeline—Dyspepsia—Methotrexate—esophageal cancer	0.000477	0.000731	CcSEcCtD
Cevimeline—Decreased appetite—Methotrexate—esophageal cancer	0.000471	0.000722	CcSEcCtD
Cevimeline—Fatigue—Methotrexate—esophageal cancer	0.000467	0.000716	CcSEcCtD
Cevimeline—Pain—Methotrexate—esophageal cancer	0.000463	0.00071	CcSEcCtD
Cevimeline—Vomiting—Capecitabine—esophageal cancer	0.000462	0.000709	CcSEcCtD
Cevimeline—Rash—Capecitabine—esophageal cancer	0.000459	0.000703	CcSEcCtD
Cevimeline—Dermatitis—Capecitabine—esophageal cancer	0.000458	0.000703	CcSEcCtD
Cevimeline—Headache—Capecitabine—esophageal cancer	0.000456	0.000699	CcSEcCtD
Cevimeline—Feeling abnormal—Methotrexate—esophageal cancer	0.000446	0.000684	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000443	0.000679	CcSEcCtD
Cevimeline—Nausea—Capecitabine—esophageal cancer	0.000432	0.000663	CcSEcCtD
Cevimeline—Urticaria—Methotrexate—esophageal cancer	0.00043	0.00066	CcSEcCtD
Cevimeline—Abdominal pain—Methotrexate—esophageal cancer	0.000428	0.000656	CcSEcCtD
Cevimeline—Body temperature increased—Methotrexate—esophageal cancer	0.000428	0.000656	CcSEcCtD
Cevimeline—Hypersensitivity—Methotrexate—esophageal cancer	0.000399	0.000612	CcSEcCtD
Cevimeline—Asthenia—Methotrexate—esophageal cancer	0.000389	0.000596	CcSEcCtD
Cevimeline—Pruritus—Methotrexate—esophageal cancer	0.000383	0.000588	CcSEcCtD
Cevimeline—Diarrhoea—Methotrexate—esophageal cancer	0.00037	0.000568	CcSEcCtD
Cevimeline—Dizziness—Methotrexate—esophageal cancer	0.000358	0.000549	CcSEcCtD
Cevimeline—Vomiting—Methotrexate—esophageal cancer	0.000344	0.000528	CcSEcCtD
Cevimeline—FMO1—Metabolism—HMOX1—esophageal cancer	0.000344	0.000988	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000344	0.000988	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CXCL2—esophageal cancer	0.000342	0.000984	CbGpPWpGaD
Cevimeline—Rash—Methotrexate—esophageal cancer	0.000341	0.000524	CcSEcCtD
Cevimeline—Dermatitis—Methotrexate—esophageal cancer	0.000341	0.000523	CcSEcCtD
Cevimeline—CHRM3—GPCR ligand binding—CXCL2—esophageal cancer	0.000341	0.00098	CbGpPWpGaD
Cevimeline—Headache—Methotrexate—esophageal cancer	0.000339	0.00052	CcSEcCtD
Cevimeline—FMO1—Metabolism—ABCB1—esophageal cancer	0.00033	0.000948	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000328	0.000942	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GDI2—esophageal cancer	0.000326	0.000937	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GDI2—esophageal cancer	0.000325	0.000934	CbGpPWpGaD
Cevimeline—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000323	0.000929	CbGpPWpGaD
Cevimeline—Nausea—Methotrexate—esophageal cancer	0.000322	0.000493	CcSEcCtD
Cevimeline—CHRM1—GPCR ligand binding—ANXA1—esophageal cancer	0.000318	0.000914	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—ANXA1—esophageal cancer	0.000317	0.000911	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—NOS2—esophageal cancer	0.000316	0.000909	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—SST—esophageal cancer	0.000309	0.000889	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—SST—esophageal cancer	0.000308	0.000887	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—GHRL—esophageal cancer	0.000302	0.000867	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000301	0.000864	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—GHRL—esophageal cancer	0.000301	0.000864	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SLC52A3—esophageal cancer	0.000294	0.000846	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—BLVRB—esophageal cancer	0.000294	0.000846	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000286	0.000822	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000283	0.000813	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000268	0.00077	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000252	0.000725	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AKAP13—esophageal cancer	0.000251	0.000723	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CA1—esophageal cancer	0.00025	0.00072	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SLC10A2—esophageal cancer	0.00025	0.00072	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KMT2D—esophageal cancer	0.000236	0.000677	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KMT2D—esophageal cancer	0.000235	0.000675	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000231	0.000663	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PDE4D—esophageal cancer	0.00023	0.000661	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKAP13—esophageal cancer	0.000229	0.000659	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CA2—esophageal cancer	0.000229	0.000658	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKAP13—esophageal cancer	0.000228	0.000656	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000228	0.000655	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000225	0.000646	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—CREBBP—esophageal cancer	0.000221	0.000634	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GNG7—esophageal cancer	0.000219	0.000631	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GNG7—esophageal cancer	0.000219	0.000629	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000214	0.000616	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PLCE1—esophageal cancer	0.000213	0.000612	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ADH7—esophageal cancer	0.000213	0.000612	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000211	0.000607	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00021	0.000604	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PDE4D—esophageal cancer	0.00021	0.000602	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—EGFR—esophageal cancer	0.00021	0.000602	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ADCYAP1—esophageal cancer	0.000209	0.000602	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PDE4D—esophageal cancer	0.000209	0.0006	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—EGFR—esophageal cancer	0.000209	0.0006	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GNG7—esophageal cancer	0.000199	0.000573	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GNG7—esophageal cancer	0.000199	0.000571	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—NOS3—esophageal cancer	0.000197	0.000568	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—EP300—esophageal cancer	0.000193	0.000556	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000193	0.000556	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CXCL2—esophageal cancer	0.000193	0.000554	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—WWOX—esophageal cancer	0.000192	0.000552	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—WWOX—esophageal cancer	0.000191	0.00055	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ADH1B—esophageal cancer	0.000187	0.000537	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FKBP1A—esophageal cancer	0.000183	0.000525	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FKBP1A—esophageal cancer	0.000182	0.000524	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—esophageal cancer	0.000182	0.000523	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—PIK3CA—esophageal cancer	0.000181	0.000521	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PTGS2—esophageal cancer	0.000181	0.000519	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—ANXA1—esophageal cancer	0.00018	0.000517	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—ANXA1—esophageal cancer	0.000179	0.000515	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—WIF1—esophageal cancer	0.000179	0.000513	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TYMP—esophageal cancer	0.000178	0.000513	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—WIF1—esophageal cancer	0.000178	0.000512	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000176	0.000506	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000176	0.000506	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CXCL2—esophageal cancer	0.000176	0.000505	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CXCL2—esophageal cancer	0.000175	0.000503	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—SST—esophageal cancer	0.000175	0.000503	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—SST—esophageal cancer	0.000174	0.000501	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP26A1—esophageal cancer	0.000174	0.000499	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GHRL—esophageal cancer	0.00017	0.00049	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GHRL—esophageal cancer	0.00017	0.000488	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALOX15—esophageal cancer	0.000169	0.000486	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000165	0.000474	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CSNK1A1—esophageal cancer	0.000164	0.000472	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—ANXA1—esophageal cancer	0.000163	0.000469	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—ANXA1—esophageal cancer	0.000163	0.000468	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTO1—esophageal cancer	0.000161	0.000464	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TPI1—esophageal cancer	0.000161	0.000464	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—SST—esophageal cancer	0.000159	0.000456	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—SST—esophageal cancer	0.000158	0.000455	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000156	0.000449	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000156	0.000448	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GHRL—esophageal cancer	0.000155	0.000445	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALDOB—esophageal cancer	0.000155	0.000445	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GHRL—esophageal cancer	0.000154	0.000443	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PFN1—esophageal cancer	0.000154	0.000443	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PFN1—esophageal cancer	0.000154	0.000442	CbGpPWpGaD
Cevimeline—CHRM1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000152	0.000436	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000151	0.000434	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—EP300—esophageal cancer	0.00015	0.000432	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.00015	0.00043	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CA1—esophageal cancer	0.00015	0.00043	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GAPDH—esophageal cancer	0.000149	0.000428	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CRABP1—esophageal cancer	0.000148	0.000424	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GNG7—esophageal cancer	0.00014	0.000403	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ELMO1—esophageal cancer	0.000138	0.000398	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TP53—esophageal cancer	0.000138	0.000398	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ELMO1—esophageal cancer	0.000138	0.000397	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CA2—esophageal cancer	0.000137	0.000394	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000136	0.00039	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKAP13—esophageal cancer	0.000135	0.000389	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000135	0.000389	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKAP13—esophageal cancer	0.000135	0.000388	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALDH2—esophageal cancer	0.000132	0.000378	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000127	0.000366	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000127	0.000366	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTT1—esophageal cancer	0.000125	0.00036	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000125	0.000359	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000125	0.000358	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PDE4D—esophageal cancer	0.000124	0.000356	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP2A6—esophageal cancer	0.000124	0.000355	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PDE4D—esophageal cancer	0.000123	0.000355	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GNG7—esophageal cancer	0.000118	0.000338	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GNG7—esophageal cancer	0.000117	0.000337	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ENO1—esophageal cancer	0.000117	0.000337	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS1—esophageal cancer	0.000117	0.000337	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PSME2—esophageal cancer	0.000116	0.000332	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PSME1—esophageal cancer	0.000116	0.000332	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000115	0.000331	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000115	0.000331	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000112	0.000321	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PIK3CA—esophageal cancer	0.000111	0.000319	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—XIAP—esophageal cancer	0.00011	0.000317	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—XIAP—esophageal cancer	0.00011	0.000316	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000107	0.000307	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CTNNA1—esophageal cancer	0.000104	0.0003	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CTNNA1—esophageal cancer	0.000104	0.000299	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000104	0.000298	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CXCL2—esophageal cancer	0.000104	0.000298	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CXCL2—esophageal cancer	0.000103	0.000297	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000101	0.000291	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP1B1—esophageal cancer	9.97e-05	0.000287	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.79e-05	0.000281	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CA1—esophageal cancer	9.79e-05	0.000281	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PSME2—esophageal cancer	9.69e-05	0.000279	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PSME1—esophageal cancer	9.69e-05	0.000279	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PSME1—esophageal cancer	9.66e-05	0.000278	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PSME2—esophageal cancer	9.66e-05	0.000278	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTO1—esophageal cancer	9.65e-05	0.000277	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TPI1—esophageal cancer	9.65e-05	0.000277	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ANXA1—esophageal cancer	9.64e-05	0.000277	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ANXA1—esophageal cancer	9.61e-05	0.000276	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SST—esophageal cancer	9.38e-05	0.00027	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP19A1—esophageal cancer	9.37e-05	0.000269	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SST—esophageal cancer	9.35e-05	0.000269	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALDOB—esophageal cancer	9.25e-05	0.000266	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH3—esophageal cancer	9.14e-05	0.000263	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GHRL—esophageal cancer	9.14e-05	0.000263	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GHRL—esophageal cancer	9.11e-05	0.000262	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH3—esophageal cancer	9.11e-05	0.000262	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FBXW7—esophageal cancer	8.99e-05	0.000259	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FBXW7—esophageal cancer	8.97e-05	0.000258	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CA2—esophageal cancer	8.95e-05	0.000257	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GAPDH—esophageal cancer	8.9e-05	0.000256	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CRABP1—esophageal cancer	8.82e-05	0.000254	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—HMOX1—esophageal cancer	8.55e-05	0.000246	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GNG7—esophageal cancer	8.39e-05	0.000241	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PLCE1—esophageal cancer	8.32e-05	0.000239	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADH7—esophageal cancer	8.32e-05	0.000239	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ABCB1—esophageal cancer	8.21e-05	0.000236	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	8.2e-05	0.000236	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH2—esophageal cancer	8.17e-05	0.000235	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALDH2—esophageal cancer	7.86e-05	0.000226	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTT1—esophageal cancer	7.48e-05	0.000215	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.39e-05	0.000213	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.3e-05	0.00021	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	7.27e-05	0.000209	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFBR2—esophageal cancer	7.25e-05	0.000208	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ENO1—esophageal cancer	7.01e-05	0.000201	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS1—esophageal cancer	7.01e-05	0.000201	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TYMP—esophageal cancer	6.97e-05	0.0002	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSME2—esophageal cancer	6.91e-05	0.000199	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSME1—esophageal cancer	6.91e-05	0.000199	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	6.89e-05	0.000198	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SMAD4—esophageal cancer	6.86e-05	0.000197	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.78e-05	0.000195	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.61e-05	0.00019	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.31e-05	0.000181	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TPI1—esophageal cancer	6.31e-05	0.000181	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.05e-05	0.000174	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP1B1—esophageal cancer	5.96e-05	0.000171	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.82e-05	0.000167	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.77e-05	0.000166	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	5.63e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HIF1A—esophageal cancer	5.62e-05	0.000161	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP19A1—esophageal cancer	5.6e-05	0.000161	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GNG7—esophageal cancer	5.49e-05	0.000158	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CREBBP—esophageal cancer	5.49e-05	0.000158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KDR—esophageal cancer	5.39e-05	0.000155	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KDR—esophageal cancer	5.37e-05	0.000154	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.14e-05	0.000148	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HMOX1—esophageal cancer	5.11e-05	0.000147	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	5.08e-05	0.000146	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	5.06e-05	0.000145	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NOS3—esophageal cancer	4.91e-05	0.000141	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ABCB1—esophageal cancer	4.91e-05	0.000141	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.89e-05	0.000141	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.83e-05	0.000139	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	4.6e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	4.59e-05	0.000132	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ENO1—esophageal cancer	4.58e-05	0.000132	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.58e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	4.52e-05	0.00013	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSME2—esophageal cancer	4.52e-05	0.00013	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSME1—esophageal cancer	4.52e-05	0.00013	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	4.51e-05	0.00013	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS2—esophageal cancer	4.49e-05	0.000129	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	4.32e-05	0.000124	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	4.31e-05	0.000124	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOS3—esophageal cancer	4.12e-05	0.000118	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOS3—esophageal cancer	4.11e-05	0.000118	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	3.92e-05	0.000113	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	3.91e-05	0.000112	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.9e-05	0.000112	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	3.85e-05	0.000111	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	3.84e-05	0.00011	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—EP300—esophageal cancer	3.74e-05	0.000107	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.66e-05	0.000105	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCND1—esophageal cancer	3.41e-05	9.79e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCND1—esophageal cancer	3.39e-05	9.76e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.34e-05	9.61e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	3.29e-05	9.47e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	3.28e-05	9.44e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.28e-05	9.43e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.21e-05	9.22e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EP300—esophageal cancer	3.13e-05	9.01e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EP300—esophageal cancer	3.12e-05	8.98e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NOS3—esophageal cancer	2.94e-05	8.44e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CA—esophageal cancer	2.76e-05	7.94e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—esophageal cancer	2.73e-05	7.85e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—esophageal cancer	2.72e-05	7.83e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.69e-05	7.72e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGFR—esophageal cancer	2.67e-05	7.68e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGFR—esophageal cancer	2.66e-05	7.65e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	2.32e-05	6.66e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	2.31e-05	6.64e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—esophageal cancer	2.24e-05	6.45e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—esophageal cancer	2.24e-05	6.43e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—EP300—esophageal cancer	2.23e-05	6.42e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.14e-05	6.16e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NOS3—esophageal cancer	1.92e-05	5.52e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.76e-05	5.05e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.65e-05	4.75e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—EP300—esophageal cancer	1.46e-05	4.2e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.08e-05	3.11e-05	CbGpPWpGaD
